Transaction DateRecipientSharesTypePriceValue
8th September 2020Bros. Advisors Lp Baker6,151Open or private purchase$47.39$291,479.90
8th September 2020Bros. Advisors Lp Baker15,807Open or private purchase$47.04$743,482.25
8th September 2020Bros. Advisors Lp Baker15,172Open or private purchase$47.47$720,199.67
8th September 2020Bros. Advisors Lp Baker76,473Open or private purchase$47.39$3,623,856.64
8th September 2020Bros. Advisors Lp Baker185Open or private purchase$45.88$8,486.88
8th September 2020Bros. Advisors Lp Baker1,220Open or private purchase$47.47$57,912.18
8th September 2020Bros. Advisors Lp Baker1,272Open or private purchase$47.04$59,828.52
8th September 2020Bros. Advisors Lp Baker15Open or private purchase$45.88$688.13
4th September 2020Bros. Advisors Lp Baker26,238Open or private purchase$47.26$1,239,984.27
4th September 2020Bros. Advisors Lp Baker712Open or private purchase$47.50$33,818.72
Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals Ltd. logo

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company. Its products include Rilonacept, Mavrilimumab and KPL-716. The company was founded in July 2015 and is headquartered in Hamilton, Bermuda.

Ticker: KNSA
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1730430
Employees: 111
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $123 M (163%)
Assets, Current: $264 M (9%)
Property, Plant and Equipment, Net: $5 M (0%)
Assets: $271 M (6%)
Accounts Payable, Current: $2 M (-58%)
Accrued Liabilities, Current: $16 M (0%)
Liabilities, Current: $21 M (-26%)
Other Liabilities, Noncurrent: $334 Th (2%)
Liabilities: $21 M (-27%)
Retained Earnings (Accumulated Deficit): $420 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $9 Th (-72%)
Stockholders' Equity (Parent): $250 M (0%)
Liabilities and Equity: $271 M (6%)
Research and Development: $22 M (-48%)
General and Administrative Expenses: $10 M (-47%)
Operating Income/Loss: $32 M (-47%)
Provision for income taxes: $6 M (0%)